#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to recognize that cannabis use disorder is emerging in early adolescence, requiring age-appropriate screening and intervention protocols in pediatric and primary care settings. Understanding the accessibility factors driving youth cannabis use can inform patient education and family-based prevention strategies that address the actual barriers adolescents face. Early identification and treatment of cannabis use disorder in children may prevent progression to more severe substance use patterns and associated developmental harms during critical brain maturation periods.
Children as young as 11 years old are presenting to Children’s National Hospital with cannabis use disorder requiring clinical treatment, reflecting both early initiation of cannabis use and the accessibility of the drug to minors in the community. Clinicians report that pediatric patients cite ease of access as a significant factor in their cannabis use, suggesting that current regulatory and enforcement mechanisms may be insufficient to prevent youth access despite legal restrictions in most jurisdictions. This trend has important implications for pediatric practice, as cannabis use disorder in childhood and early adolescence can interfere with neurodevelopment, academic performance, and mental health during critical developmental windows. Pediatricians and addiction specialists should maintain heightened awareness of cannabis use as a presenting concern in younger populations and screen for problematic use patterns during routine visits. The clinical takeaway is that healthcare providers caring for children and adolescents should actively assess for cannabis use and counsel families about access prevention, while recognizing that pediatric cannabis use disorder is an increasingly common condition requiring evidence-based treatment and intervention.
“What we’re seeing clinically is that early-onset cannabis use in children often signals underlying anxiety, ADHD, or trauma that’s going untreated, and the cannabis becomes a maladaptive coping mechanism rather than the primary problem. The real issue isn’t that cannabis is uniquely dangerous to developing brains at this age, though it does carry real risks, but that we’re failing these kids by not addressing the root causes while simultaneously allowing them easy access to a product that delays necessary mental health intervention.”
🧠 While cannabis use disorder in children has historically been uncommon, emerging data from pediatric treatment centers suggests increasing prevalence among younger adolescents, reflecting broader shifts in product availability, potency, and normalized attitudes toward cannabis use. Clinicians should recognize that early-onset cannabis use in this age group may signal underlying vulnerabilities including mood or behavioral disorders, peer influence, or environmental stressors that warrant comprehensive assessment alongside substance use screening. The gap between perceived risk and actual use patterns in youth mirrors historical trends with other substances and underscores the importance of not dismissing cannabis concerns in pediatric visits. Important confounders include changing product formulations (particularly high-THC concentrates), regional legalization effects on accessibility, and difficulty distinguishing problematic use from experimental use in developing adolescents whose decision-making capacity continues to mature. Practically, pediatricians should incorporate brief cannabis-specific screening into routine adolescent assessments, recognize that even
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: